Nonsurgical Skin Cancer Care and New Approvals, With Todd Schlesinger, MD
FDA approved Biofrontera's Ameluz for superficial basal cell carcinoma, showing 66% efficacy in trials. Regeneron's cemiplimab and Novartis' remibrutinib also gained approvals for skin cancer and dermographism. Dermatologist Todd Schlesinger discussed these advancements and ongoing research at a conference.
How this was made
The 30-second read
Why it matters
Regulatory approvals provide immediate positive catalysts for the involved pharma companies, while broader sector sentiment remains cautiously optimistic.
Market read
New FDA approvals create short‑term upside potential for the named companies and reinforce confidence in biotech pipeline activity.
What to watch
Potential reimbursement challenges and the need for real‑world evidence to support uptake.
Background
The article reviews recent FDA approvals for nonsurgical skin‑cancer therapies and discusses emerging treatments.
Ticker impact
FDA approved Regeneron's cemiplimab (Libtayo) as adjuvant therapy for high‑risk cutaneous squamous cell carcinoma.
likely upward pressure as investors price in additional sales potential.
First‑time FDA approval for a high‑risk skin cancer indication; Regeneron already markets the drug, so incremental revenue is expected.
FDA approved Novartis' remibrutinib (Rhapsido) for symptomatic dermographism, extending its label beyond chronic spontaneous urticaria.
moderate upside as the label expansion may boost future sales.
Label extension adds a new patient population; however, market impact may be limited by the niche indication.
Market effects
Strengthens the dermatology/oncology biotech segment with new FDA approvals.
US biotech sector may see modest gains from regulatory tailwinds.
Highlights continued pipeline success for large‑cap pharma firms.
Counterpoint
The niche indications may limit revenue upside, and competition could erode market share.
Key entities
- companyRegeneron Pharmaceuticals
Manufacturer of cemiplimab (Libtayo).
- companyNovartis AG
Manufacturer of remibrutinib (Rhapsido).
